Search

Your search keyword '"Jia, Xiao-Chi"' showing total 41 results
Start Over Author "Jia, Xiao-Chi"
41 results on '"Jia, Xiao-Chi"'

7. Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells

Author

Armen Mardiros, Jia Xiao-Chi, Richard Chang, Arianne Perez, David D. Chang, Jeffrey S. Wiezorek, Sean Yoder, Steven A. Rosenberg, Yueh Wei-Shen, James N. Kochenderfer, Lynn Navale, William Y. Go, Adrian Bot, and Margo Roberts

Subjects
Cancer Research, business.industry, T cell, Anti cd19, complex mixtures, Chimeric antigen receptor, Interleukin 21, medicine.anatomical_structure, Oncology, Immunology, medicine, Biomarker Analysis, Car t cells, business, B cell, Clin oncol
Abstract

3028 Background: CAR engineered autologous T cell therapy has shown promising efficacy in B cell malignancies in an ongoing phase 1 study (Kochenderfer et al. J Clin Oncol 2014, ASH 2014). Anti-CD1...

Published
2015
Full Text
View/download PDF

11. Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia

Author

Pereira, Daniel S., primary, Guevara, Claudia, additional, Verlinsky, Alla, additional, Virata, Cyrus, additional, Ssucheng, J Hsu, additional, An, Zili, additional, Zhang, Chungying, additional, Dinh, Nick, additional, Avina, Hector, additional, Do, Lisa, additional, Karki, Sher, additional, Abad, Joseph, additional, Yang, Peng, additional, Ou, Jimmy, additional, Morrison, Karen, additional, Moon, Sing-Ju, additional, Malik, Faisal, additional, Jin, Liqing, additional, Choi, Michael, additional, Wu, Christina, additional, Anand, Banmeet, additional, Cooper, Scott, additional, Joseph, Ingrid, additional, Jia, Xiao-Chi, additional, Morrison, Kendall, additional, Challita-Eid, Pia, additional, Donate, Fernando, additional, Kipps, Thomas, additional, Dick, John, additional, and Stover, David, additional

Published
2014
Full Text
View/download PDF

12. In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates

Author

Jackson, Dowdy, primary, Atkinson, John, additional, Guevara, Claudia I., additional, Zhang, Chunying, additional, Kery, Vladimir, additional, Moon, Sung-Ju, additional, Virata, Cyrus, additional, Yang, Peng, additional, Lowe, Christine, additional, Pinkstaff, Jason, additional, Cho, Ho, additional, Knudsen, Nick, additional, Manibusan, Anthony, additional, Tian, Feng, additional, Sun, Ying, additional, Lu, Yingchun, additional, Sellers, Aaron, additional, Jia, Xiao-Chi, additional, Joseph, Ingrid, additional, Anand, Banmeet, additional, Morrison, Kendall, additional, Pereira, Daniel S., additional, and Stover, David, additional

Published
2014
Full Text
View/download PDF

13. Abstract 2832: Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of solid tumors

Author

Satpayev, Daulet, primary, Torgov, Michael, additional, Yang, Peng, additional, Morrison, Karen, additional, Shostak, Yuriy, additional, Raitano, Art, additional, Liu, Wendy, additional, Lortie, Dawn, additional, An, Zili, additional, Capo, Linnette, additional, Leavitt, Monica, additional, Perez, Myra, additional, Verlinsky, Alla, additional, Shirasuna, Kenna, additional, Avina, Hector, additional, Guevara, Claudia, additional, Morrison, Kendall, additional, Challita-Eid, Pia, additional, Jia, Xiao-Chi, additional, Gudas, Jean, additional, and Stover, David, additional

Published
2011
Full Text
View/download PDF

14. Abstract 4566: AGS-1C4D4: A fully human anti-PSCA antibody inhibits tumor formation and metastasis in orthotopic models of pancreatic cancer

Author

Navas, Tony, primary, Haubrich, Trisha, additional, Llamas, Jenny, additional, Avina, Hector, additional, Chunying, Zhang, additional, Perez, Myra, additional, Capo, Linnette, additional, Leavitt, Monica, additional, Chen, Rou-Yu, additional, Verlinsky, Alla, additional, An, Zili, additional, Secrest, James, additional, Ganguly, Nandini, additional, Satpayev, Daulet, additional, Morrison, Karen, additional, Raitano, Art, additional, Challita-Eid, Pia, additional, Jia, Xiao-Chi, additional, Morrison, Kendall, additional, Hartford, Alan, additional, and Stover, David, additional

Published
2011
Full Text
View/download PDF

17. Monoclonal Antibodies to Six-Transmembrane Epithelial Antigen of the Prostate-1 Inhibit Intercellular Communication In vitro and Growth of Human Tumor Xenografts In vivo

Author

Challita-Eid, Pia M., primary, Morrison, Kendall, additional, Etessami, Soudabeh, additional, An, Zili, additional, Morrison, Karen J., additional, Perez-Villar, Juan J., additional, Raitano, Arthur B., additional, Jia, Xiao-Chi, additional, Gudas, Jean M., additional, Kanner, Steven B., additional, and Jakobovits, Aya, additional

Published
2007
Full Text
View/download PDF

18. Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met–Dependent Human Tumors

Author

Burgess, Teresa, primary, Coxon, Angela, additional, Meyer, Susanne, additional, Sun, Jan, additional, Rex, Karen, additional, Tsuruda, Trace, additional, Chen, Qing, additional, Ho, Shu-Yin, additional, Li, Luke, additional, Kaufman, Stephen, additional, McDorman, Kevin, additional, Cattley, Russell C., additional, Sun, Jilin, additional, Elliott, Gary, additional, Zhang, Ke, additional, Feng, Xiao, additional, Jia, Xiao-Chi, additional, Green, Larry, additional, Radinsky, Robert, additional, and Kendall, Richard, additional

Published
2006
Full Text
View/download PDF

21. Production of Human Antibodies from Transgenic Mice.

Author

Walker, John M., Lo, Benny K. C., Davis, C. Geoffrey, Jia, Xiao-Chi, Feng, Xiao, and Haak-Frendscho, Mary

Abstract

Mice transgenic for human immunoglobulin genes offer the opportunity to investigators to derive fully human antibodies using well-established hybridoma technology. Several different strains of such mice are available, and can be obtained under certain conditions from various commercial entities (1-3). The brand names of these mice include XenoMouse®, HuMAb® Mouse, TC™ mouse, and KM™ mouse. The leading transgenic mice all share certain properties. These include the following: 1.the endogenous murine heavy-chain locus has been inactivated by knocking out either all of the JH genes or the Cμ gene (4);2.the endogenous murine kappa light-chain locus has been inactivated by knocking out the Jκ and/or the Cκ genes;3.the endogenous murine lambda light-chain locus remains intact and functional;4.the human heavy-chain transgene contains, at minimum, the majority of the human VH genes, all the D genes, all the JH genes, Cμ Cδ, and at least one Cγ gene, together with regulatory elements; and5.the human kappa light-chain transgene contains the majority of the human Vκ genes, all the Jκ genes, and the Cκ gene, together with regulatory elements. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

22. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

Author

Mendez, Michael J., primary, Green, Larry L., additional, Corvalan, Jose R.F., additional, Jia, Xiao-Chi, additional, Maynard-Currie, Catherine E., additional, Yang, Xiao-dong, additional, Gallo, Michael L., additional, Louie, Donna M., additional, Lee, Doris V., additional, Erickson, Karen L., additional, Luna, Jac, additional, Roy, Catherine M.-N., additional, Abderrahim, Hadi, additional, Kirschenbaum, Ford, additional, Noguchi, Masato, additional, Smith, Douglas H., additional, Fukushima, Atsushi, additional, Hales, Joanna F., additional, Finer, Mitchell H., additional, Davis, C. Geoffrey, additional, Zsebo, Krisztina M., additional, and Jakobovits, Aya, additional

Published
1997
Full Text
View/download PDF

23. In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates.

Author

Jackson, Dowdy, Atkinson, John, Guevara, Claudia I., Zhang, Chunying, Kery, Vladimir, Moon, Sung-Ju, Virata, Cyrus, Yang, Peng, Lowe, Christine, Pinkstaff, Jason, Cho, Ho, Knudsen, Nick, Manibusan, Anthony, Tian, Feng, Sun, Ying, Lu, Yingchun, Sellers, Aaron, Jia, Xiao-Chi, Joseph, Ingrid, and Anand, Banmeet

Subjects
CYSTEINE, ANTIBODY-drug conjugates, IN vitro studies, TRASTUZUMAB, ANTINEOPLASTIC agents, DRUG delivery systems, GENE expression, DRUG development
Abstract

Antibody drug conjugates (ADCs) are monoclonal antibodies designed to deliver a cytotoxic drug selectively to antigen expressing cells. Several components of an ADC including the selection of the antibody, the linker, the cytotoxic drug payload and the site of attachment used to attach the drug to the antibody are critical to the activity and development of the ADC. The cytotoxic drugs or payloads used to make ADCs are typically conjugated to the antibody through cysteine or lysine residues. This results in ADCs that have a heterogeneous number of drugs per antibody. The number of drugs per antibody commonly referred to as the drug to antibody ratio (DAR), can vary between 0 and 8 drugs for a IgG1 antibody. Antibodies with 0 drugs are ineffective and compete with the ADC for binding to the antigen expressing cells. Antibodies with 8 drugs per antibody have reduced in vivo stability, which may contribute to non target related toxicities. In these studies we incorporated a non-natural amino acid, para acetyl phenylalanine, at two unique sites within an antibody against Her2/neu. We covalently attached a cytotoxic drug to these sites to form an ADC which contains two drugs per antibody. We report the results from the first direct preclinical comparison of a site specific non-natural amino acid anti-Her2 ADC and a cysteine conjugated anti-Her2 ADC. We report that the site specific non-natural amino acid anti-Her2 ADCs have superior in vitro serum stability and preclinical toxicology profile in rats as compared to the cysteine conjugated anti-Her2 ADCs. We also demonstrate that the site specific non-natural amino acid anti-Her2 ADCs maintain their in vitro potency and in vivo efficacy against Her2 expressing human tumor cell lines. Our data suggests that site specific non-natural amino acid ADCs may have a superior therapeutic window than cysteine conjugated ADCs. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

31. Bioactive Follicle-Stimulating Hormone Levels in Serum and Urine of Male and Female Rats from Birth to Prepubertal Period1

Author

Dahl, Kristine D., Jia, Xiao-Chi, and Hsueh, Aaron J . W.

Abstract

Using a sensitive in vitro granulosa cell aromatase bioassay (GAB), w e determined serum and urinary levels of bioactive follicle-stimulating hormone (bio-FSH) in male and female rats from birth to Day 40 of age. In addition, serum immunoreactive FSH (immuno-FSH) was measured by radioimmunoassay to determine the bio- to immuno-(B/I) ratio of FSH. During the neonatal period (Days 1–7 of age), both sexes bud detectable serum bio-FSN levels. In the infantile period (Days 7–21), serum bio-FSH levels initially decreased ut Day 10 f o r both sexes, and then rose steadily, reaching maximum concentrations at Day 14 (males: 68.7 ng/ml; females: 114.6 ng/ml). Subsequently, FSH levels in the females decreased from Day 16 throughout the juvenile (Days 21–35) and prepubertal (Days 35–40) periods. In contrast, FSH levels in the males fluctuated during these periods. In the males, immuno-FSH reflected the bioactive profiles, with a B/I ratio of 2.2 ± 0.2. In the females, the B/I ratio was approximately 2.5 during the neonatal and infantile periods but declined to approximately 1.0 during the juvenile and prepubertal periods, consistent with earlier observations of heterogeneous forms of pituitary FSH in immature female rats. Morning urine samples were also collected daily and bio-FSH concentrations were determined. In both sexes, urinary bio-FSH profiles were highly correlated ( r = 0.93) with serum FSH throughout development. However, the urine concentrations were about 50-fold higher than serum. This study demonstrates that (I) urine bio-FSH levels reflect serum bio-FSH levels; (2) serum bio-FSH levels in male rats, in general, reflect immuno-FSH profiles; and (3) serum B/I ratios of FSH in females decrease during the juvenile and prepubertal periods, suggesting the transition from birth to sexual maturity is accompanied by qualitative changes in the circulating forms of FSH.

Published
1988
Full Text
View/download PDF

41. Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.

Author

LaRochelle WJ, Jeffers M, Corvalan JR, Jia XC, Feng X, Vanegas S, Vickroy JD, Yang XD, Chen F, Gazit G, Mayotte J, Macaluso J, Rittman B, Wu F, Dhanabal M, Herrmann J, and Lichenstein HS

Subjects
3T3 Cells, Animals, Cell Transformation, Neoplastic, Humans, Immunohistochemistry, Mice, Mice, SCID, Neoplasms blood, Neoplasms pathology, Phosphorylation, Platelet-Derived Growth Factor biosynthesis, Platelet-Derived Growth Factor genetics, RNA, Messenger biosynthesis, RNA, Messenger genetics, Receptor, Platelet-Derived Growth Factor beta metabolism, Receptor, Platelet-Derived Growth Factor beta physiology, Signal Transduction physiology, Tumor Cells, Cultured, Neoplasms metabolism, Platelet-Derived Growth Factor physiology
Abstract

Platelet-derived growth factor (PDGF) has been directly implicated in developmental and physiological processes, as well as in human cancer and other proliferative disorders. We have recently isolated and characterized a novel protease-activated member of the PDGF family, PDGF D. PDGF D has been shown to be proliferative for cells of mesenchymal origin, signaling through PDGF receptors. Comprehensive and systematic PDGF D transcript analysis revealed expression in many cell lines derived from ovarian, renal, and lung cancers, as well as from astrocytomas and medulloblastomas. beta PDGF receptor profiling further suggested autocrine signaling in several brain tumor cell lines. PDGF D transforming ability and tumor formation in SCID mice was further demonstrated. Exploiting a sensitive PDGF D sandwich ELISA using fully human monoclonal antibodies, PDGF D was detected at elevated levels in the sera of ovarian, renal, lung, and brain cancer patients. Immunohistochemical analysis confirmed PDGF D localization to ovarian and lung tumor tissues. Together, these data demonstrate that PDGF D plays a role in certain human cancers.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results